Literature DB >> 17646200

Invasive Candida species infection: the importance of adequate empirical antifungal therapy.

Darius Armstrong-James1.   

Abstract

Candida species are a common cause of bloodstream and invasive infection in critically ill and immunosuppressed patients. Furthermore, invasive Candida infection carries a poor prognosis and may initially be mistaken for bacterial infection. An article in this issue of the Journal investigates the relationship between adequacy of initial empirical therapy and outcome from invasive Candida infection. This study shows that adequate empirical therapy is received by only a quarter of patients, and that inappropriate therapy is associated with increased mortality. These findings highlight the importance of appropriate empirical therapy in invasive Candida infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646200     DOI: 10.1093/jac/dkm260

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.

Authors:  Thomas R Fritsche; Paul R Rhomberg; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

3.  Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia.

Authors:  Jesús Guinea; Sandra Recio; Pilar Escribano; Marta Torres-Narbona; Teresa Peláez; Carlos Sánchez-Carrillo; Marta Rodríguez-Créixems; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

4.  Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2010-12-15       Impact factor: 5.948

5.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Authors:  M A Pfaller; S A Messer; R J Hollis; L Boyken; S Tendolkar; J Kroeger; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

6.  An observational study on the epidemiological and mycological profile of Candidemia in ICU patients.

Authors:  Aarti Kotwal; Debasis Biswas; Jagdish Prasad Sharma; Alpa Gupta; Parul Jindal
Journal:  Med Sci Monit       Date:  2011-11

7.  FungalRV: adhesin prediction and immunoinformatics portal for human fungal pathogens.

Authors:  Rupanjali Chaudhuri; Faraz Alam Ansari; Muthukurussi Varieth Raghunandanan; Srinivasan Ramachandran
Journal:  BMC Genomics       Date:  2011-04-15       Impact factor: 3.969

Review 8.  Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013.

Authors:  Arezoo Ahmadi; Seyed Hossein Ardehali; Mohammad Taghi Beigmohammadi; Mahboubeh Hajiabdolbaghi; Seyed Mohammad Reza Hashemian; Mehran Kouchek; Ali Majidpour; Majid Mokhtari; Omid Moradi Moghaddam; Atabak Najafi; Reza Nejat; Mohammad Niakan; Amir Hossein Lotfi; Ali Amirsavadkouhi; Farzad Shirazian; Payam Tabarsi; Mahshid Talebi Taher; Mohammad Torabi-Nami
Journal:  JRSM Open       Date:  2014-02-26

9.  Comparison of the Sensititre YeastOne antifungal method with the CLSI M27-A3 reference method to determine the activity of antifungal agents against clinical isolates of Candidaspp.

Authors:  Rabiye Altinbaş; Ayşe Barış; Sümeyye Şen; Recep Öztürk; Nuri Kiraz
Journal:  Turk J Med Sci       Date:  2020-12-17       Impact factor: 0.973

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.